<DOC>
	<DOC>NCT00244504</DOC>
	<brief_summary>Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months</brief_summary>
	<brief_title>Moxonidine in Patients Undergoing Vascular Surgery</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Moxonidine</mesh_term>
	<criteria>abdominal aortic or peripheral vascular surgery unstable angina, severe symptomatic heart failure (NYHA IV) systolic blood pressure at rest &lt; 100 mmHg bradycardia (&lt;50/min) higher grade AV heart block creatinine clearance &lt; 30 ml/min pregnancy no consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>